0.94; p = 0.008), diabetes (HR, 0.57; p = 0.047), pre-transplant MELD (HR, 0.93; p = 0.027), AFP by log scale (HR, 1.18; p = 0.022), bridging therapy (HR, 0.10; p < 0.001 for none and HR, 2.14; p = 0.028 for systemic versus locoregional), viable tumor number (HR, 1.06; p = 0.031), maximum tumor size (HR, 1.18; p = 0.003), microvascular invasion (HR, 2.45; p = 0.001), and platelet-lymphocyte ratio (HR, 1.00; p = 0.013). Here, AFP is linked to neoplasm.